GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Vimta Labs Ltd (NSE:VIMTALABS) » Definitions » Cyclically Adjusted PS Ratio

Vimta Labs (NSE:VIMTALABS) Cyclically Adjusted PS Ratio : 4.42 (As of May. 19, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Vimta Labs Cyclically Adjusted PS Ratio?

As of today (2024-05-19), Vimta Labs's current share price is ₹493.80. Vimta Labs's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was ₹111.68. Vimta Labs's Cyclically Adjusted PS Ratio for today is 4.42.

The historical rank and industry rank for Vimta Labs's Cyclically Adjusted PS Ratio or its related term are showing as below:

NSE:VIMTALABS' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.05   Med: 3.69   Max: 5.74
Current: 4.42

During the past years, Vimta Labs's highest Cyclically Adjusted PS Ratio was 5.74. The lowest was 1.05. And the median was 3.69.

NSE:VIMTALABS's Cyclically Adjusted PS Ratio is ranked worse than
70.68% of 133 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.36 vs NSE:VIMTALABS: 4.42

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Vimta Labs's adjusted revenue per share data for the three months ended in Dec. 2023 was ₹36.276. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ₹111.68 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Vimta Labs Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Vimta Labs's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vimta Labs Cyclically Adjusted PS Ratio Chart

Vimta Labs Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 1.91 3.35 3.00

Vimta Labs Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.37 4.26 3.00 5.26 3.61

Competitive Comparison of Vimta Labs's Cyclically Adjusted PS Ratio

For the Diagnostics & Research subindustry, Vimta Labs's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vimta Labs's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Vimta Labs's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Vimta Labs's Cyclically Adjusted PS Ratio falls into.



Vimta Labs Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Vimta Labs's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=493.80/111.68
=4.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vimta Labs's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Vimta Labs's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=36.276/152.9243*152.9243
=36.276

Current CPI (Dec. 2023) = 152.9243.

Vimta Labs Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201312 14.060 91.425 23.518
201403 13.287 91.425 22.225
201406 12.992 94.103 21.113
201409 11.252 96.780 17.779
201412 11.220 96.780 17.729
201503 12.966 97.163 20.407
201506 12.711 99.841 19.469
201509 15.366 101.753 23.093
201512 13.391 102.901 19.901
201603 14.932 102.518 22.274
201606 16.864 105.961 24.338
201609 17.092 105.961 24.667
201612 17.388 105.196 25.277
201703 18.374 105.196 26.710
201706 17.473 107.109 24.947
201709 19.769 109.021 27.730
201712 20.999 109.404 29.352
201803 23.473 109.786 32.696
201806 24.659 111.317 33.876
201809 24.337 115.142 32.323
201812 22.981 115.142 30.522
201903 24.216 118.202 31.330
201906 19.952 120.880 25.241
201909 19.276 123.175 23.932
201912 23.272 126.235 28.192
202003 18.514 124.705 22.703
202006 14.846 127.000 17.876
202009 26.866 130.118 31.575
202012 26.542 130.889 31.010
202103 26.115 131.771 30.307
202106 27.749 134.084 31.648
202109 33.394 135.847 37.592
202112 29.802 138.161 32.987
202203 32.057 138.822 35.314
202206 35.106 142.347 37.714
202209 36.104 144.661 38.166
202212 34.079 145.763 35.753
202303 35.005 146.865 36.449
202309 33.146 151.492 33.459
202312 36.276 152.924 36.276

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vimta Labs  (NSE:VIMTALABS) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Vimta Labs Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Vimta Labs's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vimta Labs (NSE:VIMTALABS) Business Description

Traded in Other Exchanges
Address
Plot No.141/2 & 142, IDA, Phase-II, Cherlapally, R. R. District, Hyderabad, TG, IND, 500051
Vimta Labs Ltd is a comprehensive contract research and testing organization, providing a wide range of services to pharmaceutical, biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device, and many other industries. Its services portfolio includes testing and contract research services in the fields of clinical research, pre-clinical research, clinical diagnostics, biopharma services, analytical testing, and research and environmental studies. The group generates principal revenue from the provision of testing and analysis services.

Vimta Labs (NSE:VIMTALABS) Headlines

No Headlines